InMed Pharmaceuticals (INM) Competitors $2.30 -0.02 (-0.86%) Closing price 04:00 PM EasternExtended Trading$2.26 -0.04 (-1.70%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. IMNN, NRSN, TRIB, MTEX, LPCN, LEXX, SYBX, MTVA, PRPH, and LSBShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Imunon (IMNN), NeuroSense Therapeutics (NRSN), Trinity Biotech (TRIB), Mannatech (MTEX), Lipocine (LPCN), Lexaria Bioscience (LEXX), Synlogic (SYBX), MetaVia (MTVA), ProPhase Labs (PRPH), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Imunon NeuroSense Therapeutics Trinity Biotech Mannatech Lipocine Lexaria Bioscience Synlogic MetaVia ProPhase Labs LakeShore Biopharma InMed Pharmaceuticals (NASDAQ:INM) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Which has more volatility & risk, INM or IMNN? InMed Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Do insiders and institutionals believe in INM or IMNN? 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor INM or IMNN? In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 4 articles in the media. InMed Pharmaceuticals' average media sentiment score of 1.06 beat Imunon's score of -0.04 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is INM or IMNN more profitable? Imunon has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. InMed Pharmaceuticals' return on equity of -107.93% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-168.87% -107.93% -82.97% Imunon N/A -405.07%-158.41% Which has higher earnings and valuation, INM or IMNN? InMed Pharmaceuticals has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.60M1.00-$7.68M-$12.09-0.19Imunon$500K31.62-$18.62M-$12.95-0.50 Do analysts recommend INM or IMNN? Imunon has a consensus price target of $232.50, indicating a potential upside of 3,487.96%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryInMed Pharmaceuticals and Imunon tied by winning 8 of the 16 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.60M$2.48B$5.70B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-0.1921.6430.8625.25Price / Sales1.00545.59403.9088.50Price / CashN/A25.4525.2228.45Price / Book0.115.559.516.00Net Income-$7.68M$31.83M$3.26B$265.34M7 Day Performance2.22%4.99%4.49%2.81%1 Month Performance-13.86%4.04%5.18%1.50%1 Year Performance-18.09%11.07%31.98%25.46% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.33 of 5 stars$2.30-0.9%N/A-17.4%$4.60M$4.60M-0.1910Short Interest ↓IMNNImunon1.5234 of 5 stars$6.81-3.9%$232.50+3,316.6%-62.6%$16.49M$500K-0.5230Gap UpNRSNNeuroSense Therapeutics2.5209 of 5 stars$1.21+0.8%$14.00+1,058.0%+54.5%$16.47MN/A-2.2310News CoverageAnalyst ForecastShort Interest ↑Gap DownTRIBTrinity Biotech1.474 of 5 stars$0.90+7.9%N/A-33.1%$16.44M$61.56M-0.31480Upcoming EarningsMTEXMannatech0.4368 of 5 stars$8.65+8.1%N/A+21.7%$16.44M$117.87M-86.50250Earnings ReportShort Interest ↑Gap DownLPCNLipocine3.0306 of 5 stars$3.00+1.7%$9.00+200.0%-18.1%$16.26M$11.20M-3.4510LEXXLexaria Bioscience3.7814 of 5 stars$0.82-0.2%$4.00+387.8%-74.2%$16.04M$460K-1.227Short Interest ↓SYBXSynlogic0.9571 of 5 stars$1.40-0.4%N/A+2.8%$16.03M$10K-0.5580Short Interest ↑MTVAMetaVia2.4745 of 5 stars$0.65+1.9%$7.50+1,053.3%N/A$15.74MN/A0.008Analyst RevisionPRPHProPhase Labs1.0738 of 5 stars$0.37+31.7%N/A-86.0%$15.70M$6.77M-0.30130Earnings ReportGap DownHigh Trading VolumeLSBLakeShore Biopharma1.5057 of 5 stars$0.75-6.9%N/A-84.1%$15.52M$85.67M0.00773News CoveragePositive NewsUpcoming EarningsShort Interest ↓Gap Up Related Companies and Tools Related Companies IMNN Alternatives NRSN Alternatives TRIB Alternatives MTEX Alternatives LPCN Alternatives LEXX Alternatives SYBX Alternatives MTVA Alternatives PRPH Alternatives LSB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access